CDA-2, a Urinary Preparation, Inhibits Lung Cancer Development through the Suppression of NF-kappaB Activation in Myeloid Cell

• Xuan Wang,

  Affiliation Department of Pharmacy, Putuo People’s Hospital, Shanghai, China

  ⨯
• Cui-Min Jiang,

  Affiliation Department of Pharmacy, Putuo People’s Hospital, Shanghai, China

  ⨯
• Hai-Ying Wan,

  Affiliation Department of Clinical Laboratory, Tongji Hospital of Tongji University, Shanghai, China

  ⨯
• Jun-Lu Wu,

  Affiliation Department of Clinical Laboratory, Tongji Hospital of Tongji University, Shanghai, China

  ⨯
• Wen-Qiang Quan,

  Affiliation Department of Clinical Laboratory, Tongji Hospital of Tongji University, Shanghai, China

  ⨯
• Robert Bals,

  Affiliation Department of Internal Medicine V – Pulmonology, Allergology, Respiratory Intensive Care Medicine, Saarland University Hospital, Homburg, Germany

  ⨯
• Kai-Yin Wu,

  Affiliation Institute of Pathology, Charité University Hospital, Berlin, Germany

  ⨯
• Dong Li

  * E-mail: 186ld@163.com

  Affiliation Department of Clinical Laboratory, Tongji Hospital of Tongji University, Shanghai, China

  ⨯